Cytomics Limited is a development stage startup based in Hong Kong offering proprietary computational biology solutions that provide new types of SINGLE CELL TYPE biomarkers for applications in disease diagnosis and prognosis.
We have a product readily used as companion diagnostics for cancer vaccine to identify patients who are likely to have favorable response to vaccine treatment. It spins out from our earlier work in development of a rapid response biomarker for COVID vaccination. cytomics.com.cn/en/new-patent/2/ New Generation of blood test for vaccination
Experimental cancer vaccine shows promise in animal studies
NIH researchers find IV administration improves tumor-fighting action